InvestorsHub Logo
Followers 53
Posts 3618
Boards Moderated 0
Alias Born 06/07/2011

Re: specular post# 10678

Thursday, 07/24/2014 4:31:11 AM

Thursday, July 24, 2014 4:31:11 AM

Post# of 12450
Actually, it was worse than I thought... I knew there would be no revenue before 2016 on the migraine drug, but I thought it would be approved by the end of 2014. Turns out, according to Horst, that it won't be approved, if at all, until 2nd quarter 2015. In my opinion, that pushes any potential revenue out to 3rd quarter 2016... By that time, sales may be equivalent to Forfivo, and we know what happened there!

The Suboxone drug with Par is a very long ways out, and negligible at this point, but Horst talks about filing a ANDA for the second Par drug in 2015...

At this point, IGXT is a swing trader stock, not a long term investment. Buying at this price is a good deal, as long as you sell on the news, like when they announce that they have filed the application for Europe this quarter!

Remarkably, even though it is back down to what is considered normal prices for IGXT, I still have no interest in jumping in just yet...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IGXT News